Drug intelligence / Profile preview

HIVconsvX

Development stage: Unknown
Lead developer: University of Oxford
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

HIVconsvX is an investigational T cell–inducing HIV vaccine immunogen designed around conserved regions of the HIV-1 proteome to elicit broad, cross-clade cellular immune responses for HIV prevention and potentially functional cure. It is typically delivered using heterologous prime–boost regimens with viral vectors or nucleic acid platforms and aims to focus T cells on invariant viral epitopes that are less able to escape by mutation. Development has been led by academic and nonprofit HIV vaccine research groups working in collaboration with clinical trial networks.

Targets

Gag-Pol (HIV-1 gag-pol polyprotein)

Beyond the preview

Go deeper on HIVconsvX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIVconsvX.

Explore the full profile